Investigating the potential cytotoxic effects of an NGR tagged ruthenium-rubredoxin complex on HT-1080 fibrosarcoma cells
Location
Suwanee, GA
Start Date
7-5-2024 1:00 PM
End Date
7-5-2024 4:00 PM
Description
Introduction: Many forms of cancer, such as fibrosarcoma, present significant challenges in treatment due to their aggressive nature, individual presentation, and limited therapeutic options. In recent research, the development of anticancer agents targeting specific biomarkers such as aminopeptidase N (CD13), expressed by cancer cells like fibrosarcoma, may enhance treatment efficacy while minimizing collateral adverse effects. A promising approach involves the utilization of NGR-tagged compounds, which have demonstrated a “trojan horse” property in preclinical studies. Ruthenium-based compounds have also garnered attention as a potential alternative to platinum-based anti-neoplastic agents in treating a variety of malignancies.
Objectives: This research aimed to investigate the cytotoxic effects of an NGR-tagged ruthenium-substituted rubredoxin (NGR-RuRb) compound on fibrosarcoma cells.
Methods: Through a series of in vitro assays, including cell viability assays, apoptosis assays, and cellular uptake imaging, we have evaluated the impact of the compound on cell lines possessing an NGR receptor, aminopeptidase N. Additionally, mechanistic studies are being conducted to elucidate the underlying pathways involved in the compound's cytotoxic activity.
Results: Preliminary results demonstrate a greater dose-dependent decrease in fibrosarcoma cell viability following treatment when compared to an aminopeptidase N null cell line. The resulting images from fluorescence microscopy revealed visible fluorescence of the compound around the observed cells, suggesting its efficacy in targeted delivery to cancer cells expressing NGR-binding receptors.
Conclusion: These findings underscore the potential of NGR-tagged ruthenium-substituted rubredoxin compounds as a novel therapeutic strategy for fibrosarcoma treatment and its potential as an anti-neoplastic agent for other CD13-expressing cancer lines. Further studies are warranted to optimize compound efficacy, elucidate mechanistic effects, and evaluate its therapeutic potential in in vivo models. Ultimately an optimistic look at the effects of NGR-RuRb may translate into clinical applications for combating fibrosarcoma and other CD13 targetable malignancies.
Embargo Period
5-22-2024
Investigating the potential cytotoxic effects of an NGR tagged ruthenium-rubredoxin complex on HT-1080 fibrosarcoma cells
Suwanee, GA
Introduction: Many forms of cancer, such as fibrosarcoma, present significant challenges in treatment due to their aggressive nature, individual presentation, and limited therapeutic options. In recent research, the development of anticancer agents targeting specific biomarkers such as aminopeptidase N (CD13), expressed by cancer cells like fibrosarcoma, may enhance treatment efficacy while minimizing collateral adverse effects. A promising approach involves the utilization of NGR-tagged compounds, which have demonstrated a “trojan horse” property in preclinical studies. Ruthenium-based compounds have also garnered attention as a potential alternative to platinum-based anti-neoplastic agents in treating a variety of malignancies.
Objectives: This research aimed to investigate the cytotoxic effects of an NGR-tagged ruthenium-substituted rubredoxin (NGR-RuRb) compound on fibrosarcoma cells.
Methods: Through a series of in vitro assays, including cell viability assays, apoptosis assays, and cellular uptake imaging, we have evaluated the impact of the compound on cell lines possessing an NGR receptor, aminopeptidase N. Additionally, mechanistic studies are being conducted to elucidate the underlying pathways involved in the compound's cytotoxic activity.
Results: Preliminary results demonstrate a greater dose-dependent decrease in fibrosarcoma cell viability following treatment when compared to an aminopeptidase N null cell line. The resulting images from fluorescence microscopy revealed visible fluorescence of the compound around the observed cells, suggesting its efficacy in targeted delivery to cancer cells expressing NGR-binding receptors.
Conclusion: These findings underscore the potential of NGR-tagged ruthenium-substituted rubredoxin compounds as a novel therapeutic strategy for fibrosarcoma treatment and its potential as an anti-neoplastic agent for other CD13-expressing cancer lines. Further studies are warranted to optimize compound efficacy, elucidate mechanistic effects, and evaluate its therapeutic potential in in vivo models. Ultimately an optimistic look at the effects of NGR-RuRb may translate into clinical applications for combating fibrosarcoma and other CD13 targetable malignancies.